Figure 2.

Thymic effect of prostate cancer (PC) and ADT in mice. (A) Micrograph pictures of thymi in naïve and PC tumor- bearing mice treated with ADT. From the left to the right: hematoxylin eosin-stained thymi sections from healthy controls (CO), sham-treated PC bearing mice (PC sham), and ADT -treated PC bearing mice (PC +ADT), sacrificed at D10 post-treatment (scale bars are indicated in the graphs). (B–D). Surface assessment of overall, cortex and medulla areas in the three groups described in (A). Each dot represents one thymus. (E) Flow cytometry determination of thymocyte phenotypes at D10 post -treatment. from left to right: proportion of DN3 thymocytes (CD44^-CD25⁺ in dn), DP thymocytes (CD3⁺CD4⁺CD8⁺), sp CD4⁺ and CD8⁺, and TCRβ⁺in live cells (F). Flow cytometry determination of circulating lymphocytes at D10 post-treatment. From left to right: proportion of dn in CD3⁺ cells, DP thymocytes (CD3⁺CD4⁺CD8⁺), sp CD4⁺ and CD8⁺, and TCRβ⁺ in CD3⁺ cells. Means±SEM are depicted for 4–12 mice/group. A representative experiment is depicted for all graphs except (F) where a pool of two experiments is shown. ANOVA statistical analyses (Kruskal-Wallis test) were used for multiple comparisons. ADT, androgen deprivation therapy; ANOVA, analysis of variance.